Bayer Makes Tentative Deal in Drug-Price Probe

Article

WASHINGTON - In the first settlement of a state and federal investigation of drug-industry pricing practices, a US unit of Bayer AG has tentatively agreed to pay $14 million to resolve allegations that it caused Medicaid to overpay for its drugs. Bayer, which has confirmed a settlement, has not admitted wrongdoing. The settlement requires that the company report more accurate price information for all of its drugs to state and federal regulators. In addition, the company must cooperate with continuing investigation.

More than 20 drug companies are under current investigation, including Abbott Laboratories, Bristol-Myers Squibb Co., Glaxo Wellcome PLC's US unit, and SmithKline Beecham PLC. All companies have denied any wrongdoing. For more information visit www.hcfa.gov/medicaid.

Newsletter

Stay prepared and protected with Infection Control Today's newsletter, delivering essential updates, best practices, and expert insights for infection preventionists.

Recent Videos
Brenna Doran PhD, MA, hospital epidemiology and infection prevention for the University of California, San Francisco, and a coach and consultant of infection prevention; Jessica Swain, MBA, MLT, director of infection prevention and control for Dartmouth Health in Lebanon, New Hampshire; and Shanina Knighton, associate professor at Case Western Reserve University School of Nursing and senior nurse scientist at MetroHealth System in Cleveland, Ohio
 Brenna Doran PhD, MA, hospital epidemiology and infection prevention for the University of California, San Francisco, and a coach and consultant of infection prevention; Jessica Swain, MBA, MLT, director of infection prevention and control for Dartmouth Health in Lebanon, New Hampshire; and Shanina Knighton, associate professor at Case Western Reserve University School of Nursing and senior nurse scientist at MetroHealth System in Cleveland, Ohio
 Brenna Doran PhD, MA, hospital epidemiology and infection prevention for the University of California, San Francisco, and a coach and consultant of infection prevention; Jessica Swain, MBA, MLT, director of infection prevention and control for Dartmouth Health in Lebanon, New Hampshire; and Shanina Knighton, associate professor at Case Western Reserve University School of Nursing and senior nurse scientist at MetroHealth System in Cleveland, Ohio
© 2025 MJH Life Sciences

All rights reserved.